Cardiac and vascular diseases continue to be the most common cause of death in the western world. Globally, more than 800,000 patients undergo coronary artery bypass graft (CABG) surgery annually while about 600,000 patients have vascular surgery procedures performed. Medistim’s mission over the past three decades has been to serve patients, surgeons and health care providers with innovative and cost effective medical devices that measure blood flow and visualize atherosclerosis, and thereby help improve the quality and outcome of cardiac and vascular surgery.

Today, Medistim’s proprietary products are regarded to be standard-of-care in most European countries and Japan, while market adoption is growing in the USA, Asia and the Middle East.

Medistim is an innovator and market leader within intra-operative transit time flow measurement (TTFM) and ultrasound imaging, providing the MiraQ™ family of systems to the global market. These systems enable medical professionals to reduce risk and enhance quality of cardiac, vascular and transplant surgery.  They provide clinically relevant information that empowers surgeons to make better-informed decisions in the operating room.

 Medistim devices are developed by working closely together with surgeons, who in turn have produced a growing amount of clinical data and studies that point to their efficacy and cost-effectiveness. Medistim is committed to continuing to serve the cardiac and vascular surgeons by investing in new product development.

For more information, visit the Medistim website.